Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation

Overview

Journal Case Rep Oncol Med

Publisher Wiley

Specialty Oncology

Date 2020 Mar 25

PMID 32206360

Citations 16

Authors

Takuji Seo

Emi Noguchi

Masayuki Yoshida

Taisuke Mori

Maki Tanioka

Kazuki Sudo

Akihiko Shimomura

Kan Yonemori

Yasuhiro Fujiwara

Kenji Tamura

Affiliations

Soon will be listed here.

Abstract

Background: Metaplastic breast carcinomas are rare and carry poor prognoses. They are also more aggressive than other breast cancers and are known for their resistance to chemotherapy. Prolonged treatment with dabrafenib and trametinib is a therapy for malignant melanoma that improves the progression-free survival and overall survival. Such molecular-targeted therapies are also being developed for cancers with BRAF mutation, a driver of malignant melanoma. . A 57-year-old woman with metaplastic breast cancer and chemotherapy-refractory massive pleural effusion. After contained anthracycline regimen failure, her breast cancer progressed to an advanced stage. We ordered next-generation sequencing- (NGS-) based tumor molecular profiling from core needle biopsy of the breast. The NGS report indicated the presence of a BRAF V600E mutation. After initiation of dabrafenib and trametinib, her symptom and the pleural effusion were decreased. The first assessment of CT scans showed a decreased pleural effusion and shrunken subcutaneous lesions. Approximately 2 weeks later, a new lesion appeared. She died from 12 weeks after initiation of dabrafenib and trametinib treatment.

Conclusion: To the best of our knowledge, this is the first report of BRAF mutation breast cancer treated with dabrafenib and trametinib and it heralds the possibility of targeted therapy for rare breast cancers.

Citing Articles

Potential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.

Rojas-Salazar Y, Gomez-Montanez E, Rojas-Salazar J, Anda-Jauregui G, Hernandez-Lemus E Int J Mol Sci. 2024; 25(23).

PMID: 39684551 PMC: 11641395. DOI: 10.3390/ijms252312840.

Dissection of triple-negative breast cancer microenvironment and identification of potential therapeutic drugs using single-cell RNA sequencing analysis.

Cheng W, Mi W, Wang S, Wang X, Jiang H, Chen J J Pharm Anal. 2024; 14(8):100975.

PMID: 39263352 PMC: 11388705. DOI: 10.1016/j.jpha.2024.100975.

DeepDRA: Drug repurposing using multi-omics data integration with autoencoders.

Mohammadzadeh-Vardin T, Ghareyazi A, Gharizadeh A, Abbasi K, Rabiee H PLoS One. 2024; 19(7):e0307649.

PMID: 39058696 PMC: 11280260. DOI: 10.1371/journal.pone.0307649.

Translational Aspects in Metaplastic Breast Carcinoma.

Barrientos-Toro E, Ding Q, Raso M Cancers (Basel). 2024; 16(7).

PMID: 38611109 PMC: 11011105. DOI: 10.3390/cancers16071433.

Lung Fibroblasts Take up Breast Cancer Cell-derived Extracellular Vesicles Partially Through MEK2-dependent Macropinocytosis.

Wan Y, Zhao Y, Cao M, Wang J, Tran S, Song Z Cancer Res Commun. 2024; 4(1):170-181.

PMID: 38259097 PMC: 10802141. DOI: 10.1158/2767-9764.CRC-23-0316.

References

Reis-Filho J, Milanezi F, Carvalho S, Simpson P, Steele D, Savage K . Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res. 2005; 7(6):R1028-35. PMC: 1410747. DOI: 10.1186/bcr1341. View

Solit D, Rosen N . Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011; 364(8):772-4. DOI: 10.1056/NEJMcibr1013704. View

Reis-Filho J, Pinheiro C, Lambros M, Milanezi F, Carvalho S, Savage K . EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006; 209(4):445-53. DOI: 10.1002/path.2004. View

Pezzi C, Patel-Parekh L, Cole K, Franko J, Klimberg V, Bland K . Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2006; 14(1):166-73. DOI: 10.1245/s10434-006-9124-7. View

Okada N, Hasebe T, Iwasaki M, Tamura N, Akashi-Tanaka S, Hojo T . Metaplastic carcinoma of the breast. Hum Pathol. 2010; 41(7):960-70. DOI: 10.1016/j.humpath.2009.11.013. View

Tanabe Y, Ichikawa H, Kohno T, Yoshida H, Kubo T, Kato M . Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Mol Cancer. 2016; 15(1):73. PMC: 5112718. DOI: 10.1186/s12943-016-0553-z. View

Ross J, Badve S, Wang K, Sheehan C, Boguniewicz A, Otto G . Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Arch Pathol Lab Med. 2015; 139(5):642-9. DOI: 10.5858/arpa.2014-0200-OA. View

Long G, Fung C, Menzies A, Pupo G, Carlino M, Hyman J . Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun. 2014; 5:5694. DOI: 10.1038/ncomms6694. View

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015; 386(9992):444-51. DOI: 10.1016/S0140-6736(15)60898-4. View

10.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

11.

Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J . Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12(5):R68. PMC: 3096954. DOI: 10.1186/bcr2635. View

12.

Falchook G, Long G, Kurzrock R, Kim K, Arkenau T, Brown M . Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379(9829):1893-901. PMC: 4109288. DOI: 10.1016/S0140-6736(12)60398-5. View

13.

Weigelt B, Kreike B, Reis-Filho J . Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat. 2008; 117(2):273-80. DOI: 10.1007/s10549-008-0197-9. View

14.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

15.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

16.

Subbiah V, Kreitman R, Wainberg Z, Cho J, Schellens J, Soria J . Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2017; 36(1):7-13. PMC: 5791845. DOI: 10.1200/JCO.2017.73.6785. View

17.

Rakha E, Tan P, Varga Z, Tse G, Shaaban A, Climent F . Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Br J Cancer. 2014; 112(2):283-9. PMC: 4453452. DOI: 10.1038/bjc.2014.592. View

18.

Sen S, Meric-Bernstam F, Hong D, Hess K, Subbiah V . Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017; 109(10). PMC: 6059192. DOI: 10.1093/jnci/djx094. View

19.

Nelson R, Guye M, Luu T, Lai L . Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol. 2014; 22(1):24-31. DOI: 10.1245/s10434-014-3890-4. View

20.

Dieci M, Smutna V, Scott V, Yin G, Xu R, Vielh P . Whole exome sequencing of rare aggressive breast cancer histologies. Breast Cancer Res Treat. 2016; 156(1):21-32. DOI: 10.1007/s10549-016-3718-y. View